Effect of ex vivo treatment with rhTGFβ1 or a TGFβ1 inhibitor on monocyte responses to rgE stimulation. Monocytes and NK cells purified from PBMC collected from 10 RZV recipients (demographics in S4 Table) before vaccination (D0) and 90 days post-vaccination (D90) were combined ex vivo and stimulated with VZV-rgE. A subset of D0 monocyte & NK cocultures was also treated with the TGFβ1 inhibitor LY (D0 LY), and a subset of D90 cocultures were supplemented with rhTGFβ1. The graph shows individual data points, means and p values calculated by Friedman test for repeated measures with FDR correction. LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90. Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0. by Michael J. Johnson (5818168)

“…Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0.…”

<i>In vitro</i> characterization of the mnuA::Tn and 0690::Tn mutants. by Aga E. Gelgie (17661720)

Subjects:

DDC for four anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Isotype control overlays. by Chen Lu (135200)

Subjects:

Original uncropped blot. by Chen Lu (135200)

Subjects:

Raw Data. by Chen Lu (135200)

Subjects:

Identification of BM-MSCs. by Chen Lu (135200)

Subjects:

Olfactory function test graphical summary and results. by Myeongguk Jeong (16386165)

Subjects:

Inpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Outpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

The expenditure on anticoagulants in the period of 2019-2023(million CNY). by Wei Luo (80175)

Subjects:

Immunohistochemical staining results for OMP in olfactory bulb. by Myeongguk Jeong (16386165)

Subjects:

Effects of BM-MSCs on different types of lung cell death in different group. by Chen Lu (135200)

Subjects: